Use: Labeled indications
- Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer
- First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer
- Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE ARIMIDEX is an aromatase inhibitor indicated for:
- Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer (1.1)
- First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer (1.2)
- Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX (1.3) 1.1 Adjuvant Treatment ARIMIDEX is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment ARIMIDEX is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment ARIMIDEX is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX.
Contraindications
4 CONTRAINDICATIONS Hypersensitivity ARIMIDEX is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or to any of the excipients. Observed reactions include anaphylaxis, angioedema, and urticaria [see Adverse Reactions (6.2)]. Patients with demonstrated hypersensitivity to ARIMIDEX or any excipient (4)
US FDA labelDosing: Adult
One 1 mg tablet taken once daily (2.1)
2.1 Recommended Dose
2.1 Recommended Dose The dose of ARIMIDEX is one 1 mg tablet taken once a day. For patients with advanced breast cancer, ARIMIDEX should be continued until tumor progression. ARIMIDEX can be taken with or without food. For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown.
In the ATAC trial, ARIMIDEX was administered for five years [see Clinical Studies (14.1)]. No dosage adjustment is necessary for patients with renal impairment or for elderly patients [see Use in Specific Populations (8.6)].
2.2 Patients with Hepatic Impairment
2.2 Patients with Hepatic Impairment No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. ARIMIDEX has not been studied in patients with severe hepatic impairment [see Use in Specific Populations (8.7)].
Dosing: Altered kidney function
8.6 Renal Impairment Since only about 10% of anastrozole is excreted unchanged in the urine, the renal impairment does not influence the total body clearance. Dosage adjustment in patients with renal impairment is not necessary [see Dosage and Administration (2.1) and Clinical Pharmacology (12.3)].
Renal Impairment Anastrozole pharmacokinetics have been investigated in subjects with renal impairment. Anastrozole renal clearance decreased proportionally with creatinine clearance and was approximately 50% lower in volunteers with severe renal impairment (creatinine clearance < 30 mL/min/1.73 m²) compared to controls.
Total clearance was only reduced 10%. No dosage adjustment is needed for renal impairment [see Dosage and Administration (2.1) and Use in Specific Populations (8.6)]. Effect of Hepatic Impairment Anastrozole pharmacokinetics have been investigated in subjects with hepatic cirrhosis related to alcohol abuse. The apparent oral clearance (CL/F) of anastrozole was approximately 30% lower in subjects with stable hepatic cirrhosis than in control subjects with normal liver function.
However, these plasma concentrations were still with the range of values observed in normal subjects. The effect of severe hepatic impairment was not studied. No dose adjustment is necessary for stable hepatic cirrhosis [see Dosage and Administration (2.2) and Use in Specific Populations (8.7)].
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.7 Hepatic Impairment The plasma anastrozole concentrations in the subjects with hepatic cirrhosis were within the range of concentrations seen in normal subjects across all clinical trials. Therefore, dosage adjustment is also not necessary in patients with stable hepatic cirrhosis. ARIMIDEX has not been studied in patients with severe hepatic impairment [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)].
2.2 Patients with Hepatic Impairment No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. ARIMIDEX has not been studied in patients with severe hepatic impairment [see Use in Specific Populations (8.7)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Clinical studies in pediatric patients included a placebo-controlled trial in pubertal boys of adolescent age with gynecomastia and a single-arm trial in girls with McCune-Albright Syndrome and progressive precocious puberty. The efficacy of ARIMIDEX in the treatment of pubertal gynecomastia in adolescent boys and in the treatment of precocious puberty in girls with McCune-Albright Syndrome has not been demonstrated.
Gynecomastia Study A randomized, double-blind, placebo-controlled, multi-center study enrolled 80 boys with pubertal gynecomastia aged 11 to 18 years. Patients were randomized to a daily regimen of either ARIMIDEX 1 mg or placebo. After 6 months of treatment there was no statistically significant difference in the percentage of patients who experienced a ≥50% reduction in gynecomastia (primary efficacy analysis).
Secondary efficacy analyses (absolute change in breast volume, the percentage of patients who had any reduction in the calculated volume of gynecomastia, breast pain resolution) were consistent with the primary efficacy analysis. Serum estradiol concentrations at Month 6 of treatment were reduced by 15.4% in the ARIMIDEX group and 4.5% in the placebo group.
Adverse reactions that were assessed as treatment-related by the investigators occurred in 16.3% of the ARIMIDEX-treated patients and 8.1% of the placebo-treated patients with the most frequent being acne (7% ARIMIDEX and 2.7% placebo) and headache (7% ARIMIDEX and 0% placebo); all other adverse reactions showed small differences between treatment groups. One patient treated with ARIMIDEX discontinued the trial because of testicular enlargement.
The mean baseline-subtracted change in testicular volume after 6 months of treatment was + 6.6 ± 7.9 cm 3 in the ARIMIDEX-treated patients and + 5.2 ± 8.0 cm 3 in the placebo group. McCune-Albright Syndrome Study A multi-center, single-arm, open-label study was conducted in 28 girls with McCune-Albright Syndrome and progressive precocious puberty aged 2 to <10 years.
All patients received a 1 mg daily dose of ARIMIDEX. The trial duration was 12 months. Patients were enrolled on the basis of a diagnosis of typical (27/28) or atypical (1/27) McCune-Albright Syndrome, precocious puberty, history of vaginal bleeding, and/or advanced bone age. Patients’ baseline characteristics included the following: a mean chronological age of 5.9 ± 2.0 years, a mean bone age of 8.6 ± 2.6 years, a mean growth rate of 7.9 ± 2.9 cm/year and a mean Tanner stage for breast of 2.7 ± 0.81.
Compared to pre-treatment data there were no on-treatment statistically significant reductions in the frequency of vaginal bleeding days, or in the rate of increase of bone age (defined as a ratio between the change in bone age over the change of chronological age). There were no clinically significant changes in Tanner staging, mean ovarian volume, mean uterine volume and mean predicted adult height.
A small but statistically significant reduction of growth rate from 7.9 ± 2.9 cm/year to 6.5 ± 2.8 cm/year was observed but the absence of a control group precludes attribution of this effect to treatment or to other confounding factors such as variations in endogenous estrogen levels commonly seen in McCune-Albright Syndrome patients. Five patients (18%) experienced adverse reactions that were considered possibly related to ARIMIDEX.
These were nausea, acne, pain in an extremity, increased alanine transaminase and aspartate transaminase, and allergic dermatitis. Pharmacokinetics in Pediatric Patients Following 1 mg once daily multiple administration in pediatric patients, the mean time to reach the maximum anastrozole concentration was 1 hr. The mean (range) disposition parameters of anastrozole in pediatric patients were described by a CL/F of 1.54 L/h (0.77-4.53 L/h) and V/F of 98.4 L (50.7-330.0 L).
The terminal elimination half-life was 46.8 h, which was similar to that observed in postmenopausal women treated with anastrozole for breast cancer. Based on a population pharmacokinetic analysis, the pharmacokinetics of anastrozole was similar in boys with pubertal gynecomastia and girls with McCune-Albright Syndrome.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use In studies 0030 and 0027, about 50% of patients were 65 or older. Patients ≥ 65 years of age had moderately better tumor response and time to tumor progression than patients < 65 years of age regardless of randomized treatment. In studies 0004 and 0005, 50% of patients were 65 or older. Response rates and time to progression were similar for the over 65 and younger patients.
In the ATAC study, 45% of patients were 65 years of age or older. The efficacy of ARIMIDEX compared to tamoxifen in patients who were 65 years or older (N=1413 for ARIMIDEX and N=1410 for tamoxifen, the hazard ratio for disease-free survival was 0.93 [95% CI: 0.80, 1.08]) was less than efficacy observed in patients who were less than 65 years of age (N=1712 for ARIMIDEX and N=1706 for tamoxifen, the hazard ratio for disease-free survival was 0.79 [95% CI: 0.67, 0.94]).
The pharmacokinetics of anastrozole are not affected by age.
Dosage forms
Philippines
- Film-coated tablet: 1 mg
- Tablet: 1 mg
Registered products in the Philippines
37 products registered with the Food and Drug Administration (FDA) Philippines list Anastrozole as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Anastrazole (2 products). Products registered under these spellings are included in the table and marked.
All registered products37
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AnagalingAnastrozole | 1 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's in monocarton (Box of 100's) | RxVAT-exempt | Beta Drugs Limited.India | 2MG Incorporated | DRP-16699 | Jun 23, 2030 | |
AnaromAnastrozole | 1 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 14’s (Box of 28’s) | RxVAT-exempt | Sun Pharmaceutical Industries Ltd.India | Sun Pharma Philippines, Inc. | DRP-8734 | Dec 6, 2028 | |
Anasoma 1Anastrozole | 1 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets) | RxVAT-exempt | Eugia Pharma Specialties LimitedIndia | Medethix Inc.Trader: Aurobindo Pharma Pvt. Limited | DRP-13561 | Mar 9, 2028 | |
AnastragenAnastrozole | 1mg Film-Coated TabletAlu/Clear PVC Blister pack x 14's (Box of 2 blister pack x 14's) | RxVAT-exempt | Jodas Expoim Pvt. Ltd.India | Genace Pharma DistributorImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-11203-04 | Mar 2, 2027 | |
Anastro-cellAnastrozole | 1 mg Film-coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Haupt Pharma Munster GmbHGermany | Detoxicare Philippines. Inc.Importer: STADA Philippines Inc.Trader: STADA Arzneimittel AG | DRP-6565 | Jun 27, 2028 | |
AnastrodexAnastrozole | 1 mg Film-Coated TabletAlu/PVC Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Laboratorio Eczane Pharma S.A.Argentine Republic | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-16509-01 | Apr 3, 2030 | |
AnaxolAnastrozole | 1 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-12041 | Jun 1, 2027 | |
AnazdexAnastrozole | 1 mg Film-Coated TabletAlu/PVDC Blister pack x 14's (Box of 28's) | RxVAT-exempt | Kwang Dong Pharmaceutical Co., Ltd.Republic of Korea | JC 28 Pharmaceutical Products WholesalingImporter: JLT Pharma Inc. | DRP-11935-01 | May 20, 2027 | |
AndrazoleAnastrozole | 1 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 10's) | RxVAT-exempt | Celogen Generics Private Ltd.India | Pharmastar Int'l Trading Corp. | DRP-4995 | Dec 18, 2027 | |
AnnaGetAnastrozole | 1 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Getmeds Philippines Inc.Importer: AMB HK Enterprises Inc. | DRP-12041-01 | Jun 1, 2027 | |
AnnaGetAnastrozole | 1 mg Film-Coated TabletAlu-Clear PVC Blister Pack x 10’s monocarton (Box of 100’s) | RxVAT-exempt | Beta Drugs LimitedIndia | Getmeds Philippines Inc.Importer: 2mg Incorporated | DRP-16699-01 | Jun 23, 2030 | |
AnzolAnastrozole | 1 mg Film-coated TabletPVC/PVDC Alu Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Naprod Life Sciences Pvt. Ltd.India | Multicare Pharmaceuticals Phils. Inc. | DRP-10543 | Feb 3, 2031 | |
AnzolAnastrozole | 1 mg Film-Coated TabletAlu/PVC Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Laboratorio Eczane Pharma S.A.Argentine Republic | Multicare Pharmaceuticals Phils. Inc.Importer: Medinova Pharmaceutical Inc. | DRP-16509-02 | Apr 3, 2030 | |
AnzonatAnastrozole | 1 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Natco Pharma LimitedIndia | Natco Lifesciences Philippines Inc. | DR-XY47380 | Sep 15, 2031 | |
ArimidexAnastrozole | 1 mg TabletAlu/PVC Blister Pack x 14's (Box of 28's) | RxVAT-exempt | AstraZeneca Pharmaceuticals LPUSA | AstraZeneca Pharmaceuticals (Phils.), Inc.Trader: AstraZeneca UK Limited | DRP-9927 | May 19, 2030 | |
ArinibAnastrozole | 1 mg Film-Coated TabletAlu-PVC Blister Pack x 3's x 10 Tablets (Box of 30's); Alu-PVC Blister Pack x 2's x 14 Tablets (Box of 28's) | RxVAT-exempt | Salutas Pharma GmbHGermany | Sandoz Philippines Corporation | DRP-4050 | Oct 16, 2031 | |
ArmidaAnastrozole | 1 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | The Cathay Drug Co., Inc.Importer: AMB HK Enterprises Inc. | DRP-12041-02 | Jun 1, 2027 | |
ArmidaAnastrozole | 1 mg Film-Coated TabletOsyter White HDPE Bottle of 14 Tablets ( X 3o mL) | RxVAT-exempt | Yangtze River Pharmaceutical (Group) Co., Ltd.China | The Cathay Drug Co., Inc. | DRP-6513 | Feb 3, 2031 | |
AstezolAnastrozole | 1 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-12042 | Jun 1, 2027 | |
AstrozoleAnastrozole | 1 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 10's) | RxVAT-exempt | CELOGEN GENERICS PRIVATE LTD.India | Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp. | DRP-4995-01 | Dec 18, 2027 | |
AtrozoleAnastrozole | 1mg Film-Coated TabletAlu/PVDC Blister pack x 14's (Box of 28's) | RxVAT-exempt | Kwang Dong Pharmaceutical Co., Ltd.korea | JLT Pharma Inc. | DRP-11935 | May 20, 2027 | |
BlanestraAnastrozole | 1mg Film-Coated TabletAlu/Clear PVC Blister pack x 14's (Box of 2 blister packs x14's) | RxVAT-exempt | Jodas Expoim Pvt. Ltd.India | Bliss Pharma Distribution and Consultancy Corp. | DRP-11203 | Mar 2, 2027 | |
BlestrozoleAnastrozole | 1mg Film Coated TabletAlu/Clear PVC Blister pack x 14's (Box of 2 blister packs x 14's) | RxVAT-exempt | Jodas Expoim Pvt. Ltd.India | Bliss Pharma Distribution and Consultancy Corp. | DRP-11204 | Mar 7, 2027 | |
CastraAnastrozole | 1 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's); Alu/Clear PVC Blister Pack x 10's (Box of 10's as physician's sample) | RxVAT-exempt | Cadila Healthcare LimitedIndia | Zydus Healthcare Philippines Inc. | DRP-7216 | Oct 30, 2028 | |
EmitrozoleAnastrozole | 1 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 10's) | RxVAT-exempt | Celogen Generics Private Ltd.India | Eminent Healthcare Inc.Importer: Pharmastar Int'l Trading Corp. | DRP-4995-03 | Dec 18, 2027 | |
FobrecaneAnastrozole | 1 mg Film-Coated TabletAlu/PVC blister pack x 10's (box of 30's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Kaufmann Pharma Inc.Importer: Nelpa Lifesciences, Inc. | DR-XY48537 | Dec 22, 2027 | |
1 mg Film-Coated TabletAlu/PVC Blister Pack x 14’s (Box of 28’s) | Rx | Intas Pharmaceuticals LimitedIndia | Importer: Ambica International CorporationTrader: Ambica International Corporation | DRP-10570 | Sep 19, 2031 | ||
KemazolAnastrozole | 1 mg Film-Coated TabletAlu/ PVC Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Keminfinity Inc.Importer: AMB HK Enterprises, Inc. | DRP-12042-02 | Jun 1, 2027 | |
1mg Film-Coated TabletWhite Opaque PVC/PE/PVDC/Al Blister Pack x 14's (Box of 28's) | Rx | Synthon Hispania S.L.Spain | Macropharma CorporationTrader: Synthon BV | DR-XY45349 | May 23, 2031 | ||
NoneAnastrozole | 1 mg Film-Coated TabletAlu/Clear PVC Blister pack x 14's (Box of 2 blister packs x 14's) | RxVAT-exempt | Jodas Expoim Pvt. Ltd.India | Distribution Solutions Phils. Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-11203-01 | Mar 2, 2027 | |
NoneAnastrozole | 1 mg Film-Coated TabletAlu/Clear PVC Blister pack x 14's (Box of 2 blister packs x 14's) | RxVAT-exempt | Jodas Expoim Pvt. Ltd.India | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-11203-05 | Mar 2, 2027 | |
NovatrazoleAnastrozole | 1 mg Film-coated TabletAlu/PVC Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Laboratorio Eczane Pharma S.A.Argentina | Medinova Pharmaceutical Inc | DRP-16509 | Apr 3, 2030 | |
StrazolAnastrozole | 1 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 14's (Box of 2 Blister Packs x 14's) | RxVAT-exempt | Jodas Expoim Pvt. Ltd.India | Qualimed Pharma Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-11203-02 | Mar 2, 2027 | |
Vexal-AAnastrozole | 1 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Admac LifesciencesIndia | VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd | DRP-7020 | Dec 3, 2028 | |
WomazolAnastrozole | 1 mg Film-coated tabletAlu/Alu Foil Strip x 10's Box of 10's | RxVAT-exempt | Khandelwal Laboratories Pvt. Ltd.India | Medethix, Inc. | DRP-9876 | Mar 15, 2028 | |
ZENSTRAAnastrozole | 1 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 14's (Box of 2 blister packs x 14's) | RxVAT-exempt | Jodas Expoim Pvt. Ltd.India | Amediqo Phils., Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-11203-03 | Mar 2, 2027 | |
(no brand name)Anastrozole | 1 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets) | RxVAT-exempt | Eugia Pharma Specialties LimitedIndia | Medethix Inc.Trader: Aurobindo Pharma Pvt. Ltd. | DRP-13562 | Mar 9, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS The tablets are white, biconvex, film-coated containing 1 mg of anastrozole. The tablets are impressed on one side with a logo consisting of a letter “A” (upper case) with an arrowhead attached to the foot of the extended right leg of the “A” and on the reverse with the tablet strength marking “Adx 1”. 1 mg tablets (3)
Warnings/Precautions
- • In women with pre-existing ischemic heart disease, an increased incidence of ischemic cardiovascular events occurred with ARIMIDEX use compared to tamoxifen use. Consider risks and benefits. (5.1, 6.1)
- • Decreases in bone mineral density may occur. Consider bone mineral density monitoring. (5.2, 6.1)
- • Increases in total cholesterol may occur. Consider cholesterol monitoring. (5.3, 6.1)
- • Embryo-Fetal Toxicity: ARIMIDEX may cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception. (5.4, 8.1)
5.1 Ischemic Cardiovascular Events
5.1 Ischemic Cardiovascular Events In women with pre-existing ischemic heart disease, an increased incidence of ischemic cardiovascular events was observed with ARIMIDEX in the ATAC trial (17% of patients on ARIMIDEX and 10% of patients on tamoxifen). Consider risk and benefits of ARIMIDEX therapy in patients with pre-existing ischemic heart disease [see Adverse Reactions (6.1)].
5.2 Bone Effects Results from
5.2 Bone Effects Results from the ATAC trial bone substudy at 12 and 24 months demonstrated that patients receiving ARIMIDEX had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline. Patients receiving tamoxifen had a mean increase in both lumbar spine and total hip BMD compared to baseline.
Consider bone mineral density monitoring in patients treated with ARIMIDEX [see Adverse Reactions (6.1)].
5.3 Cholesterol During
5.3 Cholesterol During the ATAC trial, more patients receiving ARIMIDEX were reported to have elevated serum cholesterol compared to patients receiving tamoxifen (9% versus 3.5%, respectively) [see Adverse Reactions (6.1)].
5.4 Embryo-Fetal Toxicity
5.4 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, ARIMIDEX can cause fetal harm when administered to a pregnant woman. Anastrozole caused embryo-fetal toxicities in rats at maternal exposure that were 9 times the human clinical exposure, based on area under the curve (AUC). In rabbits, anastrozole caused pregnancy failure at doses equal to or greater than 16 times the recommended human dose on a mg/m 2 basis.
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during therapy with ARIMIDEX and for at least 3 weeks after the last dose [see Use in Specific Populations (8.1, 8.3) and Clinical Pharmacology (12.1)].
Drug interactions
- • Tamoxifen: Do not use in combination with ARIMIDEX. No additional benefit seen over tamoxifen monotherapy. (7.1, 14.1)
- • Estrogen-containing products: Combination use may diminish activity of ARIMIDEX. (7.2)
7.1 Tamoxifen
7.1 Tamoxifen Co-administration of anastrozole and tamoxifen in breast cancer patients reduced anastrozole plasma concentration by 27%. However, the co-administration of anastrozole and tamoxifen did not affect the pharmacokinetics of tamoxifen or N-desmethyltamoxifen. At a median follow-up of 33 months, the combination of ARIMIDEX and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor-positive subpopulation.
This treatment arm was discontinued from the trial [see Clinical Studies (14.1)]. Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole.
7.2 Estrogen
7.2 Estrogen Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action.
7.3 Warfarin
7.3 Warfarin In a study conducted in 16 male volunteers, anastrozole did not alter the exposure (as measured by C max and AUC) and anticoagulant activity (as measured by prothrombin time, activated partial thromboplastin time, and thrombin time) of both R- and S-warfarin.
7.4 Cytochrome P450
7.4 Cytochrome P450 Based on in vitro and in vivo results, it is unlikely that co-administration of ARIMIDEX 1 mg will affect other drugs as a result of inhibition of cytochrome P450 [see Clinical Pharmacology (12.3)].
Adverse reactions
Serious adverse reactions with ARIMIDEX occurring in less than 1 in 10,000 patients, are: 1) skin reactions such as lesions, ulcers, or blisters; 2) allergic reactions with swelling of the face, lips, tongue, and/or throat. This may cause difficulty in swallowing and/or breathing; and 3) changes in blood tests of the liver function, including inflammation of the liver with symptoms that may include a general feeling of not being well, with or without jaundice, liver pain or liver swelling [see Adverse Reactions (6.2)].
Common adverse reactions (occurring with an incidence of ≥10%) in women taking ARIMIDEX included: hot flashes, asthenia, arthritis, pain, arthralgia, hypertension, depression, nausea and vomiting, rash, osteoporosis, fractures, back pain, insomnia, headache, bone pain, peripheral edema, increased cough, dyspnea, pharyngitis and lymphedema. In the ATAC trial, the most common reported adverse reaction (>0.1%) leading to discontinuation of therapy for both treatment groups was hot flashes, although there were fewer patients who discontinued therapy as a result of hot flashes in the ARIMIDEX group.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In …
6.1 Clinical Trials Experience Adjuvant Therapy
6.1 Clinical Trials Experience Adjuvant Therapy Adverse reaction data for adjuvant therapy are based on the ATAC trial [see Clinical Studies (14.1)]. The median duration of adjuvant treatment for safety evaluation was 59.8 months and 59.6 months for patients receiving ARIMIDEX 1 mg and tamoxifen 20 mg, respectively. Adverse reactions occurring with an incidence of at least 5% in either treatment group during treatment or within 14 days of the end of treatment are presented in Table 1.
Table 1 - Adverse reactions occurring with an incidence of at least 5% in either treatment group during treatment, or within 14 days of the end of treatment in the ATAC trial The combination arm was discontinued due to lack of efficacy benefit at 33 months of follow-up. Body system and adverse reactions by COSTART preferred term COSTART Coding Symbols for Thesaurus of Adverse Reaction Terms.
A patient may have had more than 1 adverse reaction, including more than 1 adverse reaction in the same body system. ARIMIDEX 1 mg (N N=Number of patients receiving the treatment. = 3092) Tamoxifen 20 mg (N = 3094) Body as a whole Asthenia 575 (19) 544 (18) Pain 533 (17) 485 (16) Back pain 321 (10) 309 (10) Headache 314 (10) 249 (8) Abdominal pain 271 (9) 276 (9) Infection 285 (9) 276 (9) Accidental injury 311 (10) 303 (10) Flu syndrome 175 (6) 195 (6) Chest pain 200 (7) 150 (5) Neoplasm 162 (5) 144 (5) Cyst 138 (5) 162 (5) Cardiovascular Vasodilatation 1104 (36) 1264 (41) Hypertension 402 (13) 349 (11) Digestive Nausea 343 (11) 335 (11) Constipation 249 (8) 252 (8) Diarrhea 265 (9) 216 (7) Dyspepsia 206 (7) 169 (6) Gastrointestinal disorder 210 (7) 158 (5) Hemic and lymphatic Lymphedema 304 (10) 341 (11) Anemia 113 (4) 159 (5) Metabolic and nutritional Peripheral edema 311 (10) 343 (11) Weight gain 285 (9) 274 (9) Hypercholesterolemia 278 (9) 108 (3.5) Musculoskeletal Arthritis 512 (17) 445 (14) Arthralgia 467 (15) 344 (11) Osteoporosis 325 (11) 226 (7) Fracture 315 (10) 209 (7) Bone pain 201 (7) 185 (6) Arthrosis 207 (7) 156 (5) Joint Disorder 184 (6) 160 (5) Myalgia 179 (6) 160 (5) Nervous system Depression 413 (13) 382 (12) Insomnia 309 (10) 281 (9) Dizziness 236 (8) 234 (8) Anxiety 195 (6) 180 (6) Paresthesia 215 (7) 145 (5) Respiratory Pharyngitis 443 (14) 422 (14) Cough increased 261 (8) 287 (9) Dyspnea 234 (8) 237 (8) Sinusitis 184 (6) 159 (5) Bronchitis 167 (5) 153 (5) Skin and appendages Rash 333 (11) 387 (13) Sweating 145 (5) 177 (6) Special Senses Cataract Specified 182 (6) 213 (7) Urogenital Leukorrhea 86 (3) 286 (9) Urinary tract infection 244 (8) 313 (10) Breast pain 251 (8) 169 (6) Breast Neoplasm 164 (5) 139 (5) Vulvovaginitis 194 (6) 150 (5) Vaginal Hemorrhage Vaginal Hemorrhage without further diagnosis. 122 (4) 180 (6) Vaginitis 125 (4) 158 (5) Certain adverse reactions and combinations of adverse reactions were prospectively specified for analysis, based on the known pharmacologic properties and side effect profiles of the two drugs (see Table 2).
Table 2 - Number of Patients with Pre-specified Adverse Reactions in ATAC Trial Patients with multiple events in the same category are counted only once in that category. ARIMIDEX N=3092 (%) Tamoxifen N=3094 (%) Odds-ratio 95% CI Hot Flashes 1104 (36) 1264 (41) 0.80 0.73 − 0.89 Musculoskeletal Events Refers to joint symptoms, including joint disorder, arthritis, arthrosis and arthralgia. 1100 (36) 911 (29) 1.32 1.19 − 1.47 Fatigue/Asthenia 575 (19) 544 (18) 1.07 0.94 − 1.22 Mood Disturbances 597 (19) 554 (18) 1.10 0.97 − 1.25 Nausea and Vomiting 393 (13) 384 (12) 1.03 0.88 − 1.19 All Fractures 315 (10) 209 (7) 1.57 1.30 − 1.88 Fractures of Spine, Hip, or Wrist 133 (4) 91 (3) 1.48 1.13 − 1.95 Wrist/Colles’ fractures 67 (2) 50 (2) Spine fractures 43 (1) 22 (1) Hip fractures 28 (1) 26 (1) Cataracts 182 (6) 213 (7) 0.85 0.69 − 1.04 Vaginal Bleeding 167 (5) 317 (10) 0.50 0.41 − 0.61 Ischemic Cardiovascular Disease 127 (4) 104 (3) 1.23 0.95 − 1.60 Vaginal Discharge 109 (4) 408 (13) 0.24 0.19 − 0.30 Venous Thromboembolic Events 87 (3) 140 (5) 0.61 0.47 − 0.80 Deep Venous Thromboembolic Events 48 (2) 74 (2) 0.64 0.45 − 0.93 Ischemic Cerebrovascular Event 62 (2) 88 (3) 0.70 0.50 − 0.97 Endometrial Cancer Percentages calculated based upon the numbers of patients with an intact uterus at baseline. 4 (0.2) 13 (0.6) 0.31 0.10 − 0.94 Ischemic Cardiovascular Events Between treatment arms in the overall population of 6186 patients, there was no statistical difference in ischemic cardiovascular events (4% ARIMIDEX vs. 3% tamoxifen).
In the overall population, angina pectoris was reported in 71/3092 (2.3%) patients in the ARIMIDEX arm and 51/3094 (1.6%) patients in the tamoxifen arm; myocardial infarction was reported in 37/3092 (1.2%) patients in the ARIMIDEX arm and 34/3094 (1.1%) patients in the tamoxifen arm. In women with pre-existing ischemic heart disease 465/6186 (7.5%), the incidence of ischemic cardiovascular events was 17% in patients on ARIMIDEX and 10% in patients on tamoxifen.
In this patient population, angina pectoris was reported in 25/216 (11.6%) patients receiving ARIMIDEX and 13/249 (5.2%) patients receiving tamoxifen; myocardial infarction was reported in 2/216 (0.9%) patients receiving ARIMIDEX and 8/249 (3.2%) patients receiving tamoxifen. Bone Mineral Density Findings Results from the ATAC trial bone substudy at 12 and 24 months demonstrated that patients receiving ARIMIDEX had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline.
Patients receiving tamoxifen had a mean increase in both lumbar spine and total hip BMD compared to baseline. Because ARIMIDEX lowers circulating estrogen levels it may cause a reduction in bone mineral density. A post-marketing trial assessed the combined effects of ARIMIDEX and the bisphosphonate risedronate on changes from baseline in BMD and markers of bone resorption and formation in postmenopausal women with hormone receptor-positive early breast cancer.
All patients received calcium and vitamin D supplementation. At 12 months, small reductions in lumbar spine bone mineral density were noted in patients not receiving bisphosphonates. Bisphosphonate treatment preserved bone density in most patients at risk of fracture. Postmenopausal women with early breast cancer scheduled to be treated with ARIMIDEX should have their bone status managed according to treatment guidelines already available for postmenopausal women at similar risk of fragility fracture.
Cholesterol During the ATAC trial, more patients receiving ARIMIDEX were reported to have an elevated serum cholesterol compared to patients receiving tamoxifen (9% versus 3.5%, respectively). A post-marketing trial also evaluated any potential effects of ARIMIDEX on lipid profile. In the primary analysis population for lipids (ARIMIDEX alone), there was no clinically significant change in LDL-C from baseline to 12 months and HDL-C from baseline to 12 months.
In secondary population for lipids (ARIMIDEX+risedronate), there also was no clinically significant change in LDL-C and HDL-C from baseline to 12 months. In both populations for lipids, there was no clinically significant difference in total cholesterol (TC) or serum triglycerides (TG) at 12 months compared with baseline.
In this trial, treatment for 12 months with ARIMIDEX alone had a neutral effect on lipid profile. Combination treatment with ARIMIDEX and risedronate also had a neutral effect on lipid profile. The trial provides evidence that postmenopausal women with early breast cancer scheduled to be treated with ARIMIDEX should be managed using the current National Cholesterol Education Program guidelines for cardiovascular risk-based management of individual patients with LDL elevations.
Other Adverse Reactions Patients receiving ARIMIDEX had an increase in joint disorders (including arthritis, arthrosis and arthralgia) compared with patients receiving tamoxifen. Patients receiving ARIMIDEX had an increase in the incidence of all fractures (specifically fractures of spine, hip and wrist) [315 (10%)] compared with patients receiving tamoxifen [209 (7%)].
Patients receiving ARIMIDEX had a higher incidence of carpal tunnel syndrome [78 (2.5%)] compared with patients receiving tamoxifen [22 (0.7%)]. Vaginal bleeding occurred more frequently in the tamoxifen-treated patients versus the ARIMIDEX-treated patients 317 (10%) versus 167 (5%), respectively. Patients receiving ARIMIDEX had a lower incidence of hot flashes, vaginal bleeding, vaginal discharge, endometrial cancer, venous thromboembolic events and ischemic cerebrovascular events compared with patients receiving tamoxifen. 10-year median follow-up Safety Results from the ATAC Trial Results are consistent with the previous analyses.
Serious adverse reactions were similar between ARIMIDEX (50%) and tamoxifen (51%).
- Cardiovascular events were consistent with the known safety profiles of ARIMIDEX and tamoxifen.
- The cumulative incidences of all first fractures (both serious and non-serious, occurring either during or after treatment) was higher in the ARIMIDEX group (15%) compared to the tamoxifen group (11%). This increased first fracture rate during treatment did not continue in the post-treatment follow-up period.
- The cumulative incidence of new primary cancers was similar in the ARIMIDEX group (13.7%) compared to the tamoxifen group (13.9%). Consistent with the previous analyses, endometrial cancer was higher in the tamoxifen group (0.8%) compared to the ARIMIDEX group (0.2%).
- The overall number of deaths (during or off-trial treatment) was similar between the treatment groups. There were more deaths related to breast cancer in the tamoxifen than in the ARIMIDEX treatment group. First-Line Therapy Adverse reactions occurring with an incidence of at least 5% in either treatment group of trials 0030 and 0027 during or within 2 weeks of the end of treatment are shown in Table 3. Table 3 - Adverse Reactions Occurring with an Incidence of at Least 5% in Trials 0030 and 0027 Body system Adverse Reaction A patient may have had more than 1 adverse event. Number (%) of subjects ARIMIDEX (N=506) Tamoxifen (N=511) Whole body Asthenia 83 (16) 81 (16) Pain 70 (14) 73 (14) Back pain 60 (12) 68 (13) Headache 47 (9) 40 (8) Abdominal pain 40 (8) 38 (7) Chest pain 37 (7) 37 (7) Flu syndrome 35 (7) 30 (6) Pelvic pain 23 (5) 30 (6) Cardiovascular Vasodilation 128 (25) 106 (21) Hypertension 25 (5) 36 (7) Digestive Nausea 94 (19) 106 (21) Constipation 47 (9) 66 (13) Diarrhea 40 (8) 33 (6) Vomiting 38 (8) 36 (7) Anorexia 26 (5) 46 (9) Metabolic and Nutritional Peripheral edema 51 (10) 41 (8) Musculoskeletal Bone pain 54 (11) 52 (10) Nervous Dizziness 30 (6) 22 (4) Insomnia 30 (6) 38 (7) Depression 23 (5) 32 (6) Hypertonia 16 (3) 26 (5) Respiratory Cough increased 55 (11) 52 (10) Dyspnea 51 (10) 47 (9) Pharyngitis 49 (10) 68 (13) Skin and appendages Rash 38 (8) 34 (8) Urogenital Leukorrhea 9 (2) 31 (6) Less frequent adverse experiences reported in patients receiving ARIMIDEX 1 mg in either Trial 0030 or Trial 0027 were similar to those reported for second-line therapy. Based on results from second-line therapy and the established safety profile of tamoxifen, the incidences of 9 pre-specified adverse event categories potentially causally related to one or both of the therapies because of their pharmacology were statistically analyzed. No significant differences were seen between treatment groups. Table 4 - Number of Patients with Pre-specified Adverse Reactions in Trials 0030 and 0027 Adverse Reaction A patient may have had more than 1 adverse reaction. Number (n) and Percentage of Patients ARIMIDEX 1 mg (N=506) n (%) NOLVADEX 20 mg (N=511) n (%) Depression 23 (5) 32 (6) Tumor Flare 15 (3) 18 (4) Thromboembolic Disease Includes pulmonary embolus, thrombophlebitis, retinal vein thrombosis. 18 (4) 33 (6) Venous 5 15 Coronary and Cerebral Includes myocardial infarction, myocardial ischemia, angina pectoris, cerebrovascular accident, cerebral ischemia and cerebral infarct. 13 19 Gastrointestinal Disturbance 170 (34) 196 (38) Hot Flushes 134 (26) 118 (23) Vaginal Dryness 9 (2) 3 (1) Lethargy 6 (1) 15 (3) Vaginal Bleeding 5 (1) 11 (2) Weight Gain 11 (2) 8 (2) Second-Line Therapy ARIMIDEX was tolerated in two controlled clinical trials (i.e., Trials 0004 and 0005), with less than 3.3% of the ARIMIDEX-treated patients and 4.0% of the megestrol acetate-treated patients withdrawing due to an adverse reaction. The principal adverse reaction more common with ARIMIDEX than megestrol acetate was diarrhea. Adverse reactions reported in greater than 5% of the patients in any of the treatment groups in these two controlled clinical trials, regardless of causality, are presented below: Table 5 - Number (n) and Percentage of Patients with Adverse Reactions in Trials 0004 and 0005 Adverse Reaction A patient may have had more than one adverse reaction. ARIMIDEX ARIMIDEX Megestrol Acetate 1 mg 10 mg 160 mg (N=262) (N=246) (N=253) n % n % n % Asthenia 42 (16) 33 (13) 47 (19) Nausea 41 (16) 48 (20) 28 (11) Headache 34 (13) 44 (18) 24 (9) Hot Flashes 32 (12) 29 (11) 21 (8) Pain 28 (11) 38 (15) 29 (11) Back Pain 28 (11) 26 (11) 19 (8) Dyspnea 24 (9) 27 (11) 53 (21) Vomiting 24 (9) 26 (11) 16 (6) Cough Increased 22 (8) 18 (7) 19 (8) Diarrhea 22 (8) 18 (7) 7 (3) Constipation 18 (7) 18 (7) 21 (8) Abdominal Pain 18 (7) 14 (6) 18 (7) Anorexia 18 (7) 19 (8) 11 (4) Bone Pain 17 (6) 26 (12) 19 (8) Pharyngitis 16 (6) 23 (9) 15 (6) Dizziness 16 (6) 12 (5) 15 (6) Rash 15 (6) 15 (6) 19 (8) Dry Mouth 15 (6) 11 (4) 13 (5) Peripheral Edema 14 (5) 21 (9) 28 (11) Pelvic Pain 14 (5) 17 (7) 13 (5) Depression 14 (5) 6 (2) 5 (2) Chest Pain 13 (5) 18 (7) 13 (5) Paresthesia 12 (5) 15 (6) 9 (4) Vaginal Hemorrhage 6 (2) 4 (2) 13 (5) Weight Gain 4 (2) 9 (4) 30 (12) Sweating 4 (2) 3 (1) 16 (6) Increased Appetite 0 (0) 1 (0) 13 (5) Other less frequent (2% to 5%) adverse reactions reported in patients receiving ARIMIDEX 1 mg in either Trial 0004 or Trial 0005 are listed below. These adverse experiences are listed by body system and are in order of decreasing frequency within each body system regardless of assessed causality. Body as a Whole: Flu syndrome; fever; neck pain; malaise; accidental injury; infection Cardiovascular: Hypertension; thrombophlebitis Hepatic: Gamma GT increased; SGOT increased; SGPT increased Hematologic: Anemia; leukopenia Metabolic and Nutritional: Alkaline phosphatase increased; weight loss Mean serum total cholesterol levels increased by 0.5 mmol/L among patients receiving ARIMIDEX. Increases in LDL cholesterol have been shown to contribute to these changes. Musculoskeletal: Myalgia; arthralgia; pathological fracture Nervous: Somnolence; confusion; insomnia; anxiety; nervousness Respiratory: Sinusitis; bronchitis; rhinitis Skin and Appendages: Hair thinning (alopecia); pruritus Urogenital: Urinary tract infection; breast pain The incidences of the following adverse reaction groups potentially causally related to one or both of the therapies because of their pharmacology, were statistically analyzed: weight gain, edema, thromboembolic disease, gastrointestinal disturbance, hot flushes, and vaginal dryness. These six groups, and the adverse reactions captured in the groups, were prospectively defined. The results are shown in the table below. Table 6 - Number (n) and Percentage of Patients with Pre-specified Adverse Reactions in Trials 0004 and 0005 Adverse Reaction Group ARIMIDEX ARIMIDEX Megestrol Acetate 1 mg 10 mg 160 mg (N=262) (N=246) (N=253) n (%) n (%) n (%) Gastrointestinal Disturbance 77 (29) 81 (33) 54 (21) Hot Flushes 33 (13) 29 (12) 35 (14) Edema 19 (7) 28 (11) 35 (14) Thromboembolic Disease 9 (3) 4 (2) 12 (5) Vaginal Dryness 5 (2) 3 (1) 2 (1) Weight Gain 4 (2) 10 (4) 30 (12)
6.2 Post-Marketing Experience
6.2 Post-Marketing Experience These adverse reactions are reported voluntarily from a population of uncertain size. Therefore, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. The following have been reported in post-approval use of ARIMIDEX:
- Hepatobiliary events including increases in alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma-GT, and bilirubin; hepatitis
- Rash including cases of mucocutaneous disorders such as erythema multiforme and Stevens-Johnson syndrome
- Cases of allergic reactions including angioedema, urticaria and anaphylaxis [see Contraindications (4)]
- Myalgia and hypercalcemia (with or without an increase in parathyroid hormone)
- Tendon disorders including tendon rupture, tendonitis, tenosynovitis, and tenosynovitis stenosans (trigger finger)
Adverse reaction frequency tables (US label) US FDA label
| Body system and adverse reactions by COSTART preferred termCOSTART Coding Symbols for Thesaurus of Adverse Reaction Terms. A patient may have had more than 1 adverse reaction, including more than 1 adverse reaction in the same body system. | ARIMIDEX 1 mg (NN=Number of patients receiving the treatment. = 3092) | Tamoxifen 20 mg (N = 3094) |
|---|---|---|
| Body as a whole | ||
| Asthenia | 575 (19) | 544 (18) |
| Pain | 533 (17) | 485 (16) |
| Back pain | 321 (10) | 309 (10) |
| Headache | 314 (10) | 249 (8) |
| Abdominal pain | 271 (9) | 276 (9) |
| Infection | 285 (9) | 276 (9) |
| Accidental injury | 311 (10) | 303 (10) |
| Flu syndrome | 175 (6) | 195 (6) |
| Chest pain | 200 (7) | 150 (5) |
| Neoplasm | 162 (5) | 144 (5) |
| Cyst | 138 (5) | 162 (5) |
| Cardiovascular | ||
| Vasodilatation | 1104 (36) | 1264 (41) |
| Hypertension | 402 (13) | 349 (11) |
| Digestive | ||
| Nausea | 343 (11) | 335 (11) |
| Constipation | 249 (8) | 252 (8) |
| Diarrhea | 265 (9) | 216 (7) |
| Dyspepsia | 206 (7) | 169 (6) |
| Gastrointestinal disorder | 210 (7) | 158 (5) |
| Hemic and lymphatic | ||
| Lymphedema | 304 (10) | 341 (11) |
| Anemia | 113 (4) | 159 (5) |
| Metabolic and nutritional | ||
| Peripheral edema | 311 (10) | 343 (11) |
| Weight gain | 285 (9) | 274 (9) |
| Hypercholesterolemia | 278 (9) | 108 (3.5) |
| Musculoskeletal | ||
| Arthritis | 512 (17) | 445 (14) |
| Arthralgia | 467 (15) | 344 (11) |
| Osteoporosis | 325 (11) | 226 (7) |
| Fracture | 315 (10) | 209 (7) |
| Bone pain | 201 (7) | 185 (6) |
| Arthrosis | 207 (7) | 156 (5) |
| Joint Disorder | 184 (6) | 160 (5) |
| Myalgia | 179 (6) | 160 (5) |
| Nervous system | ||
| Depression | 413 (13) | 382 (12) |
| Insomnia | 309 (10) | 281 (9) |
| Dizziness | 236 (8) | 234 (8) |
| Anxiety | 195 (6) | 180 (6) |
| Paresthesia | 215 (7) | 145 (5) |
| Respiratory | ||
| Pharyngitis | 443 (14) | 422 (14) |
| Cough increased | 261 (8) | 287 (9) |
| Dyspnea | 234 (8) | 237 (8) |
| Sinusitis | 184 (6) | 159 (5) |
| Bronchitis | 167 (5) | 153 (5) |
| Skin and appendages | ||
| Rash | 333 (11) | 387 (13) |
| Sweating | 145 (5) | 177 (6) |
| Special Senses | ||
| Cataract Specified | 182 (6) | 213 (7) |
| Urogenital | ||
| Leukorrhea | 86 (3) | 286 (9) |
| Urinary tract infection | 244 (8) | 313 (10) |
| Breast pain | 251 (8) | 169 (6) |
| Breast Neoplasm | 164 (5) | 139 (5) |
| Vulvovaginitis | 194 (6) | 150 (5) |
| Vaginal HemorrhageVaginal Hemorrhage without further diagnosis. | 122 (4) | 180 (6) |
| Vaginitis | 125 (4) | 158 (5) |
| ARIMIDEX N=3092 (%) | Tamoxifen N=3094 (%) | Odds-ratio | 95% CI | |
|---|---|---|---|---|
| Hot Flashes | 1104 (36) | 1264 (41) | 0.80 | 0.73 − 0.89 |
| Musculoskeletal EventsRefers to joint symptoms, including joint disorder, arthritis, arthrosis and arthralgia. | 1100 (36) | 911 (29) | 1.32 | 1.19 − 1.47 |
| Fatigue/Asthenia | 575 (19) | 544 (18) | 1.07 | 0.94 − 1.22 |
| Mood Disturbances | 597 (19) | 554 (18) | 1.10 | 0.97 − 1.25 |
| Nausea and Vomiting | 393 (13) | 384 (12) | 1.03 | 0.88 − 1.19 |
| All Fractures | 315 (10) | 209 (7) | 1.57 | 1.30 − 1.88 |
| Fractures of Spine, Hip, or Wrist | 133 (4) | 91 (3) | 1.48 | 1.13 − 1.95 |
| 67 (2) | 50 (2) | |||
| 43 (1) | 22 (1) | |||
| 28 (1) | 26 (1) | |||
| Cataracts | 182 (6) | 213 (7) | 0.85 | 0.69 − 1.04 |
| Vaginal Bleeding | 167 (5) | 317 (10) | 0.50 | 0.41 − 0.61 |
| Ischemic Cardiovascular Disease | 127 (4) | 104 (3) | 1.23 | 0.95 − 1.60 |
| Vaginal Discharge | 109 (4) | 408 (13) | 0.24 | 0.19 − 0.30 |
| Venous Thromboembolic Events | 87 (3) | 140 (5) | 0.61 | 0.47 − 0.80 |
| Deep Venous Thromboembolic Events | 48 (2) | 74 (2) | 0.64 | 0.45 − 0.93 |
| Ischemic Cerebrovascular Event | 62 (2) | 88 (3) | 0.70 | 0.50 − 0.97 |
| Endometrial CancerPercentages calculated based upon the numbers of patients with an intact uterus at baseline. | 4 (0.2) | 13 (0.6) | 0.31 | 0.10 − 0.94 |
| Body system Adverse ReactionA patient may have had more than 1 adverse event. | Number (%) of subjects | |
|---|---|---|
| ARIMIDEX (N=506) | Tamoxifen (N=511) | |
| Whole body | ||
| Asthenia | 83 (16) | 81 (16) |
| Pain | 70 (14) | 73 (14) |
| Back pain | 60 (12) | 68 (13) |
| Headache | 47 (9) | 40 (8) |
| Abdominal pain | 40 (8) | 38 (7) |
| Chest pain | 37 (7) | 37 (7) |
| Flu syndrome | 35 (7) | 30 (6) |
| Pelvic pain | 23 (5) | 30 (6) |
| Cardiovascular | ||
| Vasodilation | 128 (25) | 106 (21) |
| Hypertension | 25 (5) | 36 (7) |
| Digestive | ||
| Nausea | 94 (19) | 106 (21) |
| Constipation | 47 (9) | 66 (13) |
| Diarrhea | 40 (8) | 33 (6) |
| Vomiting | 38 (8) | 36 (7) |
| Anorexia | 26 (5) | 46 (9) |
| Metabolic and Nutritional | ||
| Peripheral edema | 51 (10) | 41 (8) |
| Musculoskeletal | ||
| Bone pain | 54 (11) | 52 (10) |
| Nervous | ||
| Dizziness | 30 (6) | 22 (4) |
| Insomnia | 30 (6) | 38 (7) |
| Depression | 23 (5) | 32 (6) |
| Hypertonia | 16 (3) | 26 (5) |
| Respiratory | ||
| Cough increased | 55 (11) | 52 (10) |
| Dyspnea | 51 (10) | 47 (9) |
| Pharyngitis | 49 (10) | 68 (13) |
| Skin and appendages | ||
| Rash | 38 (8) | 34 (8) |
| Urogenital | ||
| Leukorrhea | 9 (2) | 31 (6) |
| Adverse ReactionA patient may have had more than 1 adverse reaction. | Number (n) and Percentage of Patients | |
|---|---|---|
| ARIMIDEX 1 mg (N=506) n (%) | NOLVADEX 20 mg (N=511) n (%) | |
| Depression | 23 (5) | 32 (6) |
| Tumor Flare | 15 (3) | 18 (4) |
| Thromboembolic DiseaseIncludes pulmonary embolus, thrombophlebitis, retinal vein thrombosis. | 18 (4) | 33 (6) |
| Venous | 5 | 15 |
| Coronary and CerebralIncludes myocardial infarction, myocardial ischemia, angina pectoris, cerebrovascular accident, cerebral ischemia and cerebral infarct. | 13 | 19 |
| Gastrointestinal Disturbance | 170 (34) | 196 (38) |
| Hot Flushes | 134 (26) | 118 (23) |
| Vaginal Dryness | 9 (2) | 3 (1) |
| Lethargy | 6 (1) | 15 (3) |
| Vaginal Bleeding | 5 (1) | 11 (2) |
| Weight Gain | 11 (2) | 8 (2) |
| Adverse ReactionA patient may have had more than one adverse reaction. | ARIMIDEX | ARIMIDEX | Megestrol Acetate | |||
|---|---|---|---|---|---|---|
| 1 mg | 10 mg | 160 mg | ||||
| (N=262) | (N=246) | (N=253) | ||||
| n | % | n | % | n | % | |
| Asthenia | 42 | (16) | 33 | (13) | 47 | (19) |
| Nausea | 41 | (16) | 48 | (20) | 28 | (11) |
| Headache | 34 | (13) | 44 | (18) | 24 | (9) |
| Hot Flashes | 32 | (12) | 29 | (11) | 21 | (8) |
| Pain | 28 | (11) | 38 | (15) | 29 | (11) |
| Back Pain | 28 | (11) | 26 | (11) | 19 | (8) |
| Dyspnea | 24 | (9) | 27 | (11) | 53 | (21) |
| Vomiting | 24 | (9) | 26 | (11) | 16 | (6) |
| Cough Increased | 22 | (8) | 18 | (7) | 19 | (8) |
| Diarrhea | 22 | (8) | 18 | (7) | 7 | (3) |
| Constipation | 18 | (7) | 18 | (7) | 21 | (8) |
| Abdominal Pain | 18 | (7) | 14 | (6) | 18 | (7) |
| Anorexia | 18 | (7) | 19 | (8) | 11 | (4) |
| Bone Pain | 17 | (6) | 26 | (12) | 19 | (8) |
| Pharyngitis | 16 | (6) | 23 | (9) | 15 | (6) |
| Dizziness | 16 | (6) | 12 | (5) | 15 | (6) |
| Rash | 15 | (6) | 15 | (6) | 19 | (8) |
| Dry Mouth | 15 | (6) | 11 | (4) | 13 | (5) |
| Peripheral Edema | 14 | (5) | 21 | (9) | 28 | (11) |
| Pelvic Pain | 14 | (5) | 17 | (7) | 13 | (5) |
| Depression | 14 | (5) | 6 | (2) | 5 | (2) |
| Chest Pain | 13 | (5) | 18 | (7) | 13 | (5) |
| Paresthesia | 12 | (5) | 15 | (6) | 9 | (4) |
| Vaginal Hemorrhage | 6 | (2) | 4 | (2) | 13 | (5) |
| Weight Gain | 4 | (2) | 9 | (4) | 30 | (12) |
| Sweating | 4 | (2) | 3 | (1) | 16 | (6) |
| Increased Appetite | 0 | (0) | 1 | (0) | 13 | (5) |
| Adverse Reaction Group | ARIMIDEX | ARIMIDEX | Megestrol Acetate | |||
|---|---|---|---|---|---|---|
| 1 mg | 10 mg | 160 mg | ||||
| (N=262) | (N=246) | (N=253) | ||||
| n | (%) | n | (%) | n | (%) | |
| Gastrointestinal Disturbance | 77 | (29) | 81 | (33) | 54 | (21) |
| Hot Flushes | 33 | (13) | 29 | (12) | 35 | (14) |
| Edema | 19 | (7) | 28 | (11) | 35 | (14) |
| Thromboembolic Disease | 9 | (3) | 4 | (2) | 12 | (5) |
| Vaginal Dryness | 5 | (2) | 3 | (1) | 2 | (1) |
| Weight Gain | 4 | (2) | 10 | (4) | 30 | (12) |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action, ARIMIDEX may cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no studies of ARIMIDEX use in pregnant women. Anastrozole caused embryo-fetal toxicities in rats at maternal exposure that were 9 times the human clinical exposure, based on area under the curve (AUC).
In rabbits, anastrozole caused pregnancy failure at doses equal to or greater than 16 times the recommended human dose on a mg/m 2 basis. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In animal reproduction studies, pregnant rats and rabbits received anastrozole during organogenesis at doses equal to or greater than 0.1 and 0.02 mg/kg/day, respectively, (about 1 and 1/3 the recommended human dose on a mg/m 2 basis, respectively).
In both species, anastrozole crossed the placenta, and there was increased pregnancy loss (increased pre- and/or post-implantation loss, increased resorption, and decreased numbers of live fetuses). In rats, these effects were dose related, and placental weights were significantly increased at doses equal to or greater than 0.1 mg/kg/day.
Fetotoxicity, including delayed fetal development (i.e., incomplete ossification and depressed fetal body weights), occurred in rats at anastrozole doses of 1 mg/kg/day that produced peak plasma levels 19 times higher than serum levels in humans at the therapeutic dose (AUC 0-24hr 9 times higher). In rabbits, anastrozole caused pregnancy failure at doses equal to or greater than 1.0 mg/kg/day (about 16 times the recommended human dose on a mg/m 2 basis).
Mechanism of action
12.1 Mechanism of Action The growth of many cancers of the breast is stimulated or maintained by estrogens. In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme.
Anastrozole is a selective non-steroidal aromatase inhibitor. It significantly lowers serum estradiol concentrations and has no detectable effect on formation of adrenal corticosteroids or aldosterone.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Effect on Estradiol Mean serum concentrations of estradiol were evaluated in multiple daily dosing trials with 0.5, 1, 3, 5, and 10 mg of ARIMIDEX in postmenopausal women with advanced breast cancer. Clinically significant suppression of serum estradiol was seen with all doses. Doses of 1 mg and higher resulted in suppression of mean serum concentrations of estradiol to the lower limit of detection (3.7 pmol/L).
The recommended daily dose, ARIMIDEX 1 mg, reduced estradiol by approximately 70% within 24 hours and by approximately 80% after 14 days of daily dosing. Suppression of serum estradiol was maintained for up to 6 days after cessation of daily dosing with ARIMIDEX 1 mg. The effect of ARIMIDEX in premenopausal women with early or advanced breast cancer has not been studied.
Because aromatization of adrenal androgens is not a significant source of estradiol in premenopausal women, ARIMIDEX would not be expected to lower estradiol levels in premenopausal women. Effect on Corticosteroids In multiple daily dosing trials with 3, 5, and 10 mg, the selectivity of anastrozole was assessed by examining effects on corticosteroid synthesis.
For all doses, anastrozole did not affect cortisol or aldosterone secretion at baseline or in response to ACTH. No glucocorticoid or mineralocorticoid replacement therapy is necessary with anastrozole. Other Endocrine Effects In multiple daily dosing trials with 5 and 10 mg, thyroid stimulating hormone (TSH) was measured; there was no increase in TSH during the administration of ARIMIDEX.
ARIMIDEX does not possess direct progestogenic, androgenic, or estrogenic activity in animals, but does perturb the circulating levels of progesterone, androgens, and estrogens.
Pharmacokinetics
Administration of a single 30 mg/kg or multiple 10 mg/kg doses of anastrozole to healthy subjects had no effect on the clearance of antipyrine or urinary recovery of antipyrine metabolites.
Excretion Eighty-five percent of radiolabeled anastrozole was recovered in feces and urine.
The mean elimination half-life of anastrozole is 50 hours.
Anastrozole renal clearance decreased proportionally with creatinine clearance and was approximately 50% lower in volunteers with severe renal impairment (creatinine clearance < 30 mL/min/1.73m 2 ) compared to controls.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption Inhibition of aromatase activity is primarily due to anastrozole, the parent drug. Absorption of anastrozole is rapid and maximum plasma concentrations typically occur within 2 hours of dosing under fasted conditions. Studies with radiolabeled drug have demonstrated that orally administered anastrozole is well absorbed into the systemic circulation.
Food reduces the rate but not the overall extent of anastrozole absorption. The mean C max of anastrozole decreased by 16% and the median T max was delayed from 2 to 5 hours when anastrozole was administered 30 minutes after food. The pharmacokinetics of anastrozole are linear over the dose range of 1 to 20 mg, and do not change with repeated dosing.
The pharmacokinetics of anastrozole were similar in patients and healthy volunteers. Distribution Steady-state plasma levels are approximately 3- to 4-fold higher than levels observed after a single dose of ARIMIDEX. Plasma concentrations approach steady-state levels at about 7 days of once daily dosing. Anastrozole is 40% bound to plasma proteins in the therapeutic range.
Metabolism Metabolism of anastrozole occurs by N-dealkylation, hydroxylation and glucuronidation. Three metabolites of anastrozole (triazole, a glucuronide conjugate of hydroxy-anastrozole, and a glucuronide conjugate of anastrozole itself) have been identified in human plasma and urine. The major circulating metabolite of anastrozole, triazole, lacks pharmacologic activity.
Anastrozole inhibited reactions catalyzed by cytochrome P450 1A2, 2C8/9, and 3A4 in vitro with Ki values which were approximately 30 times higher than the mean steady-state C max values observed following a 1 mg daily dose. Anastrozole had no inhibitory effect on reactions catalyzed by cytochrome P450 2A6 or 2D6 in vitro.
Administration of a single 30 mg/kg or multiple 10 mg/kg doses of anastrozole to healthy subjects had no effect on the clearance of antipyrine or urinary recovery of antipyrine metabolites. Excretion Eighty-five percent of radiolabeled anastrozole was recovered in feces and urine. Hepatic metabolism accounts for approximately 85% of anastrozole elimination.
Renal elimination accounts for approximately 10% of total clearance. The mean elimination half-life of anastrozole is 50 hours. Effect of Gender and Age Anastrozole pharmacokinetics have been investigated in postmenopausal female volunteers and patients with breast cancer. No age-related effects were seen over the range <50 to >80 years.
Effect of Race Estradiol and estrone sulfate serum levels were similar between Japanese and Caucasian postmenopausal women who received 1 mg of anastrozole daily for 16 days. Anastrozole mean steady-state minimum plasma concentrations in Caucasian and Japanese postmenopausal women were 25.7 and 30.4 ng/mL, respectively.
Effect of Renal Impairment Anastrozole pharmacokinetics have been investigated in subjects with renal impairment. Anastrozole renal clearance decreased proportionally with creatinine clearance and was approximately 50% lower in volunteers with severe renal impairment (creatinine clearance < 30 mL/min/1.73 m²) compared to controls.
Total clearance was only reduced 10%. No dosage adjustment is needed for renal impairment [see Dosage and Administration (2.1) and Use in Specific Populations (8.6)]. Effect of Hepatic Impairment Anastrozole pharmacokinetics have been investigated in subjects with hepatic cirrhosis related to alcohol abuse. The apparent oral clearance (CL/F) of anastrozole was approximately 30% lower in subjects with stable hepatic cirrhosis than in control subjects with normal liver function.
However, these plasma concentrations were still with the range of values observed in normal subjects. The effect of severe hepatic impairment was not studied. No dose adjustment is necessary for stable hepatic cirrhosis [see Dosage and Administration (2.2) and Use in Specific Populations (8.7)].
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Anastrazole 1 mg Film coated tablet | ₱49.00–₱59.00Reference ₱49.00 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Anastrazole |
| PNF listing | Oral: 1 mg film coated tablet |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. ARIMIDEX · ANI Pharmaceuticals, Inc. [US FDA-approved label, version 12, March 2, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acbfaaa9-503c-4691-9828-76a7146ed6de
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .